Black Titan Corp (NASDAQ:BTTC) Short Interest Update

Black Titan Corp (NASDAQ:BTTC) saw a large decrease in short interest during the month of July. As of July 15th, there was short interest totaling 49,987 shares, a decrease of 35.7% from the June 30th total of 77,733 shares. Based on an average daily volume of 74,298 shares, the short-interest ratio is presently 0.7 days. Currently, 1.0% of the company’s stock are short sold.

Black Titan Price Performance

Shares of Black Titan stock opened at $0.72 on Friday. The firm has a market cap of $7.79 million, a price-to-earnings ratio of -0.25 and a beta of 1.21. The firm’s 50-day moving average price is $0.85. Black Titan has a 52-week low of $0.64 and a 52-week high of $39.00. The company has a current ratio of 4.62, a quick ratio of 4.62 and a debt-to-equity ratio of 0.06.

Black Titan (NASDAQ:BTTC) last issued its quarterly earnings data on Friday, June 12th. The company reported ($0.22) earnings per share for the quarter. The company had revenue of $0.59 million for the quarter.

Institutional Investors Weigh In On Black Titan

Hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC acquired a new position in shares of Black Titan during the fourth quarter worth approximately $26,000. HRT Financial LP acquired a new position in Black Titan during the 4th quarter valued at $28,000. Marex Group plc acquired a new position in Black Titan during the 4th quarter valued at $84,000. Finally, Armistice Capital LLC bought a new stake in Black Titan in the 4th quarter valued at $840,000.

Black Titan Company Profile

Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.